{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:14:11Z","timestamp":1786407251594,"version":"build-2736575974"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"The study was sponsored by Novartis Pharma AG, Basel, Switzerland"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The incidence rate of uveitis in secukinumab-treated patients with axial spondyloarthritis (axSpA) was previously reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the incidence rate of uveitis in patients with axSpA and psoriatic arthritis (PsA) treated with secukinumab or placebo during placebo-controlled phase III studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This was a post hoc analysis from 11 phase III studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Pooled data from axSpA (MEASURE 1\u20135 and PREVENT studies) and PsA (FUTURE 1\u20135 studies) were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In the axSpA cohort (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u20091980), the incidence rate for uveitis was 1.29 per 100\u2009patient-years in the secukinumab 150\u2009mg and 1.72 per 100\u2009patient-years in the placebo arm. In the PsA cohort (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u20092453), the incidence rate for uveitis was 0.71 per 100\u2009patient-years in the secukinumab 300\u2009mg arm; no events were reported in the placebo arm.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>During the placebo-controlled phase, a numerically lower incidence of uveitis was observed in secukinumab-treated axSpA patients. In PsA patients, the incidence was low in secukinumab-treated patients, while uveitis was not reported in the placebo group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1759720x251340255","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T08:05:37Z","timestamp":1749197137000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab"],"prefix":"10.1177","volume":"17","author":[{"given":"Jan","family":"Brandt-J\u00fcrgens","sequence":"first","affiliation":[{"name":"Rheumatologische Schwerpunktpraxis, Bundesallee 104\/105, 12161 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Rudwaleit","sequence":"additional","affiliation":[{"name":"Internal Medicine and Rheumatology, Klinikum Bielefeld Rosenh\u00f6he, University of Bielefeld, Bielefeld, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[{"name":"Rheumatology University Hospital and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ritchlin","sequence":"additional","affiliation":[{"name":"Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Peterlik","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, N\u00fcrnberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhard","family":"Quebe-Fehling","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis and Rheumatic Diseases, Oregon Health &amp; Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.80.4.332"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/09286586.2022.2131837"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20951733"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11139"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2010.542269"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220263"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02549-0"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150630"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-022-02477-1"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002781"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41477"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1490-y"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0123-5"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001099"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex301"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1551-x"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-0163-5"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001600"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.12.033"},{"key":"e_1_3_4_23_2","first-page":"3621","article-title":"Uveitis status in patients with ankylosing spondylitis or psoriatic arthritis under secukinumab treatment\u2014real world data from a German observational study","volume":"73","author":"Kiltz U","year":"2021","unstructured":"Kiltz U, Brandt-Jrgens J, K\u00e4stner P, et al. Uveitis status in patients with ankylosing spondylitis or psoriatic arthritis under secukinumab treatment\u2014real world data from a German observational study. Arthritis Rheumatol 2021; 73: 3621\u20133623.","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22848"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21197"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220420"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225933"},{"key":"e_1_3_4_28_2","first-page":"465","article-title":"SER recommendations for the treatment of uveitis","volume":"19","author":"Beltr\u00e1n Catal\u00e1n E","year":"2023","unstructured":"Beltr\u00e1n Catal\u00e1n E, Brito Garc\u00eda N, Pato Cour E, et al. SER recommendations for the treatment of uveitis. Reumatol Clin (Engl Ed) 2023; 19: 465\u2013477.","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.07.008"}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X251340255","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X251340255","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X251340255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:40:06Z","timestamp":1777588806000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X251340255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":28,"alternative-id":["10.1177\/1759720X251340255"],"URL":"https:\/\/doi.org\/10.1177\/1759720x251340255","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"article-number":"1759720X251340255"}}